News & Updates
Filter by Specialty:
Does radiotherapy improve survival in NSCLC patients with cachexia?
Palliative-intent radiation was performed more frequently in patients with advanced nonsmall-cell lung cancer (NSCLC) and cachexia than those without weight loss. Unfortunately, tumour-directed therapy, whether in a curative or a palliative approach, proves inadequate in improving cachexia patient survival across all stages of the disease.
Does radiotherapy improve survival in NSCLC patients with cachexia?
06 Feb 2024Mixed nuts improve brain insulin action in overweight/obese older adults
Older adults with overweight or obesity who regularly eat mixed nuts appear to have better brain insulin action in the occipital and frontal regions, which are involved in the modulation of metabolic and cognitive processes, reports a study. They also show improvements in intrahepatic lipid content and different cardiometabolic risk markers but not in peripheral insulin sensitivity.
Mixed nuts improve brain insulin action in overweight/obese older adults
06 Feb 2024Idiopathic Parkinson’s disease: Which dopamine agonist is associated with lower risk of impulse control–related behavioural disorders?
In Chinese patients with idiopathic Parkinson’s disease (IPD) on their first dopamine agonist (DA) monotherapy for >6 months, bromocriptine is associated with a lower risk of impulse control–related behavioural disorders (ICRDs) compared with pramipexole and ropinirole, an observational cohort study in Hong Kong has shown. Rotigotine demonstrated a trend towards lower ICRD risk than the latter two DAs.
Idiopathic Parkinson’s disease: Which dopamine agonist is associated with lower risk of impulse control–related behavioural disorders?
06 Feb 2024Sitra + nivo slightly better than docetaxel in advanced NSCLC
Treatment with sitravatinib plus nivolumab (sitra + nivo) results in numerically longer median overall survival (OS), albeit statistically nonsignificant, in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC) compared with docetaxel, a study has shown.
Sitra + nivo slightly better than docetaxel in advanced NSCLC
05 Feb 2024Sacituzumab govitecan makes case as third-line therapy in mTNBC
Third-line treatment with sacituzumab govitecan works better than the physician’s treatment of choice in metastatic triple-negative breast cancer (mTNBC), an invasive histologic subtype with a poor prognosis and rapid progression, as shown in a recent study.